Abstract: The embodiments of the present disclosure relate to the technical field of cosmetics, and disclose a composition capable of enhancing an expression efficacy of an antioxidant enzyme and use thereof. The composition includes a Curcuma Longa (Turmeric) root extract and dimethylmethoxy chromanol, wherein a mass fraction ratio of the Curcuma Longa (Turmeric) root extract to the dimethylmethoxy chromanol is (0.5-3):1. A synergistic effect can be achieved in terms of promoting the expression efficacy of an antioxidant enzyme by mixing the Curcuma Longa (Turmeric) root extract and the dimethylmethoxy chromanol at a specific mass fraction ratio. Therefore, the use of the composition according to the present disclosure with the effect of promoting the expression of antioxidant enzymes in a cosmetics product and/or skin care product exerts significant skin antioxidant and anti-aging effects at a lower application amount.

Abstract: The disclosure is directed to the method of production of the composition of a cyclooxygenase-2 (COX-2) inhibitor comprising a water soluble excipient comprising HPMC, an organic acid and one or more other components. The composition may be in the form of pellets, a tablet, a capsule or granules with higher dissolution of the API or fast disintegration in the aqueous medium. In some embodiments, the composition further contains a carbonate salt to form a weakly effervescent disintegration formulation.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 ?g/day to about 100 ?g/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 ?g/day to about 160 ?g/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

Abstract: The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 ?g/day to about 100 ?g/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 ?g/day to about 160 ?g/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: A semi-solid chewable composition, comprising an herbal composition and a semi-chewable base. The herbal composition comprises anti-inflammatory, anti-microbial, analgesic, antiseptic, or antipyrelic herbal composition.

Abstract: The present disclosure provides extended release pyridostigmine compositions for symptomatic treatment of myasthenia gravis; pretreatment for exposure to the chemical nerve agent Soman; and/or the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure). The compositions of the disclosure provide reduced Fluctuation Index; reduced/blunted Cmax; higher Cmin, reduced Cmax:Cmin ratio, and reduced initial burst release of the drug, as compared to marketed pyridostigmine products. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs.

Abstract: The present disclosure provides compositions, devices, systems, methods, and kits for treatment of ophthalmic conditions. The compositions and methods of the present disclosure may include a biodegradable polymer containing an API that could be injected directly in the vitreous humor where it forms a gel and acts as a depo and delivers the drug over an extended desired period of time from 1 month to 1 years or more.

Abstract: A gel precursor composition causative of no apprehension about exhibiting cytotoxicity can be made. A method for producing a gel causative of no apprehension about exhibiting cytotoxicity, using the gel precursor composition can be performed. One of the present embodiments is a gel precursor composition including: a biocompatible polymer; a crosslinking agent to be activated by a specific substance; and a photoresponsive compound bound to the specific substance, or encompassing the specific substance.

Abstract: This patent document describes excipients that allow certain bioactive agents that exist as hydrophobic molecules to be reformulated as anions that display improved hydrophilicity, which can improve the bioavailability and pharmacokinetics of broad classes of pharmaceuticals.

Abstract: A composition containing loxoprofen sodium. The composition comprises loxoprofen sodium, sodium hyaluronate and polysorbate 80, wherein the molecular weight of sodium hyaluronate is 0.8×106?1.6×106. The composition has good stability and a long shelf life and is convenient to use.

Abstract: A long-acting brexpiprazole preparation for injection and a preparation method therefor. The preparation method therefor comprises: (a) dissolving brexpiprazole in an organic solvent to form a brexpiprazole solution; (b1) pumping the brexpiprazole solution into a sheared or violently stirred precipitation solvent, so as to precipitate brexpiprazole, or (b2) pumping the precipitation solvent into the sheared or violently stirred brexpiprazole solution, so as to precipitate brexpiprazole; (c) filtering and optionally using water to wash an obtained solid; and (d1) drying the obtained solid, and respectively packaging the dried solid and an auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection, or (d2) dispersing the obtained solid into the auxiliary material solution to obtain the long-acting brexpiprazole preparation for injection.

Abstract: Disclosed herein is composition for treating a tumor in a subject in need thereof that comprises an emulsion comprising: an aqueous carrier; and liquid lipid phase dispersed into droplets within the aqueous carrier, and a first chemotherapeutic agent within the lipid phase. In certain embodiments, the first chemotherapeutic agent comprises a first plurality of chemotherapeutic agent crystals. In certain alternative embodiments, the first chemotherapeutic agent is dissolved with the lipid phase. In certain implementations, the composition further comprises a second plurality of chemotherapeutic agent crystals within the aqueous carrier, but not the lipid phase and wherein the second plurality of chemotherapeutic agent crystals dissolves and elutes from the emulsion at a faster rate than the first plurality chemotherapeutic agent crystals. In certain implementations, the composition further comprises one or more additional chemotherapeutic agents, different from the first chemotherapeutic agent.

Abstract: A PN composition for treating multiple organ dysfunction syndrome (MODS) comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. This is a PN composition that takes up nitric oxide and releases it with enhanced rapidity enabling it to shift the balance of nitric oxide from one that exacerbates organ damage and decreased survivability to one that reverses and/or inhibits organ damage and increases survivability.

Abstract: An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.

Abstract: This disclosure provides injectable microsphere formulations capable of controlled long-term sustained release. The disclosed microsphere formulations demonstrate a zero-order release of active agents over a predetermined period of time. Also disclosed are methods of preparing the microsphere formulations and methods of use thereof. The disclosed methods can be readily scaled up while maintaining a high drug encapsulation efficiency.

Abstract: Compositions comprising ground or milled cotton fibers comprising oxidized cellulose microparticles carriers of between about 10-15.5 pm in diameter and of between about 0.5-100 pm in length, wherein the oxidized cellulose microparticles carriers contain aldehyde functional groups, and wherein the composition further comprises at least one protein or polypeptide or therapeutic compound, bound to the oxidized cellulose microparticles carrier through the aldehyde functional group.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

Abstract: The disclosure describes a solid self-emulsifying composition for oral solid dosages containing at least one cannabinoid and a method of preparing said solid self-emulsifying composition. The compositions as disclosed herein can be readily formulated into pharmaceutically acceptable oral solid dosage formulations suitable for administration to a subject in need of treatment, thereby providing certainty with regard to administration of a pre-defined therapeutically effective amount of the at least one cannabinoid.

Abstract: Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and/or second additive; or a combination thereof.

Abstract: A softgel capsule is provided which can be used with a fill composition including a high alcohol content. The softgel capsule includes a shell composition including a film forming polymer and a plasticizer. The fill composition includes at least about 20 wt. % alcohol. The softgel capsule has a weight loss change of less than about 10% after 30 days, 90 days, 6 months, 9 months or 12 months storage at ambient conditions.

Abstract: The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.

Abstract: A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

Abstract: Vesicles, including exosomes, having a coating of a hydrophilic, neutral polymer such as PEG have an increased ability to form a suspension or colloid compared to uncoated vesicles. This enables the coated vesicles to be used to form aerosol droplets such that a liquid formulation containing vesicles can be used in a nebulizer for inhaled administration thereof. Such coated vesicles are also able to pass through mucus and can deliver their cargo into lung cells. Exosomes from mesenchymal stem cells can deliver additional proteins, miRs, mRNAs and other nucleic acid sequences to lung cells providing a regenerative gene therapy for CF, COPD lung cancer and other lung diseases.

Abstract: The invention relates to a sub-micron particle comprising a payload molecule and a lipid structure being surrounded by an outer layer comprising an amphiphilic copolymer. The invention extends to method of producing the sub-micron particle. The invention also encompasses pharmaceutical compositions and vaccines comprising the sub-micron particle and medical uses thereof.

Abstract: The present invention relates to a device (100, 200, 300, 400) for the formation of organic nanoparticles configured to perform a method according to any one of the claims 12 to 18, comprising a cylindrical liquid feed line (14) for providing a first liquid at a first fluid flow velocity and a first annular liquid feed line (24) for providing a second liquid at a second fluid flow velocity, wherein the cylindrical feed line (14) and the first annular feed line (24) are coaxially arranged and the first annular feed line (24) extends around the cylindrical feed line (14), the device comprising a first inlet (12) for the introduction of the first liquid into the cylindrical feed line (14) and a second inlet (22) for the introduction of the second liquid into the first annular feed line (24), wherein the device (100, 200, 300, 400) comprises a second annular feed line (34) for providing a third liquid at a third fluid flow velocity and a third inlet (32) for the introduction of the third liquid into the second an

Abstract: Lipid nanoparticles and compositions thereof are disclosed herein. An exemplary nanoparticle composition includes an ionizable lipid, a phospholipid, a PEG-lipid, and a cholesterol modified with a hydroxyl group near the D-sterol ring. The disclosed nanoparticle compositions can target liver Kupffer cells and endothelial cells more preferentially than hepatocytes which should be beneficial in treating liver diseases in which dysfunctional Kupffer cells and endothelial cells are involved in disease pathogenesis.

Abstract: The present disclosure pertains to biodegradable polymeric microspheres that comprise a biodegradable polymer and an immunotherapeutic agent selected from an inhibitor of poly ADP ribose polymerase enzyme (PARP inhibitor) and/or a Toll-like receptor (TLR) agonist wherein (a) 50% of a total amount of the immunotherapeutic agent in the biodegradable polymeric microspheres is released from the biodegradable polymeric microspheres into a 37° C. solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; (b) between 1 mg and 100 mg of immunotherapeutic agent per 1 g dry weight of microspheres is released from the biodegradable polymeric microspheres into a 37° C. solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; or (c) both (a) and (b). Other aspects of the present disclosure pertain to methods of using such microparticles and kits that contain such microparticles.

Abstract: Embodiments described herein are directed to methods for treating moderate to severe plaque psoriasis, atopic dermatitis, or radiation dermatitis in a subject comprising administering about 1.0% tapinarof in a topical composition to the affected areas of the subject once a day for an initial period of time until the plaque psoriasis, atopic dermatitis, or radiation dermatitis is clear at which time the administration is stopped, and reassessing the subject from about 3 months to about 12 months after administration is stopped to determine if further treatment is required. Also described is the remittive effect observed after once daily administration of 1% tapinarof cream.

Abstract: Provided is a pharmaceutical composition that can treat multiple system atrophy by alleviating or suppressing the progression of the various symptoms caused by multiple system atrophy. Provided is a pharmaceutical composition for treatment of multiple system atrophy, the composition containing ubiquinol, in which the ubiquinol is subjected to oral administration repeatedly for 7 days or more at a dose of 1,500 to 1,800 mg per day.

Abstract: The disclosure provides novel compositions comprising ketamine and/or pharmaceutically acceptable salts, enantiomers, derivatives or metabolites thereof as an active pharmaceutical agent for use in the treatment, control or prevention of depressive disorders, including, for example treatment resistant depression (TRD). The disclosure further provides method and uses of combined doses of ketamine showing exceptional efficacy in the treatment of depressive disorders (including TRD) and in the control and duration of remission from the same.

Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Abstract: Among the various aspects of the present disclosure is the provision of methods of treating or preventing COVID-19 or effects thereof in a subject comprising: administering a therapeutically effective amount of a pharmaceutical agent comprising one or more of a sigma-1 receptor (S1R) agonist or antagonist, a cationic amphiphilic drug, a selective serotonin reuptake inhibitor (SSRI), or functional inhibitor of acid sphingomyelinase (FIASMA), such as fluvoxamine.

Abstract: Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.

Abstract: Provided herein are methods for using HNF4? agonists and pharmaceutical compositions thereof for reducing body weight, maintaining body weight, reducing diet induced weight gain, reducing mitochondrial stress, treating diseases or disorders such as inflammation, diabetes, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in a subject.

Abstract: The subject invention pertains to novel compounds, compositions containing the novel compounds, and methods for targeting gram-positive bacteria with the compounds or compositions of the subject invention. The subject invention further pertains to novel compounds, novel compositions, and methods for targeting gram-positive bacteria persister cells and gram-positive bacterial biofilms. The subject compounds and compositions can target gram-positive bacteria by modulating the proton motive force, calcium influx, autolysis, or any combination thereof. The novel compounds are synthetic, small molecules that can induce the death of gram-positive bacteria.

Abstract: The present invention relates to cyclopropylamide compounds that are useful in the treatment of parasitic infestations of animals. The compounds have the formula (I).

Abstract: Provided herein are inhibitors of GPX4, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the GPX4 inhibitory compounds for the modulation of ferroptosis and treatment of disease.

Abstract: The present invention relates to an application of loxoprofen sodium or a composition containing loxoprofen sodium in the preparation of a drug for preventing and/or treating the dry eye disease.

Abstract: An aqueous gel composition for topical application comprises a physiologically active ingredient, an aqueous dispersion of ethylcellulose, and a carrageenan.

Abstract: Disclosed is a method for the treatment of a neurological or movement disorder. e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof, and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, a carbidopa salt, a carbidopa prodrug, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

Abstract: The present disclosure provides compositions and methods for treating cancer with nutritionally modified diets and/or dialysis treatment, such as through amino acid depletion of one or more nonessential amino acids. In some aspects, the present disclosure provides compositions and methods for treating obesity with such modified diets and/or dialysis treatment. Furthermore, in some aspects, the present disclosure provides compositions and methods for treating renal disease with such modified diets and/or dialysis treatment.

Abstract: The invention is a multiparticulate controlled release dosage form comprising 350 mg of levodopa for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Abstract: Provided are novel methods of treatment of conditions such as peripheral tissue oxygenation, interstitial lung disease, dyspnea, ischemia from surgery, brain and pancreatic cancer with increased oxygen diffusivity comprising administering a diffusion enhancing compound, for example, trans sodium crocetinate.

Abstract: A pharmaceutical composition containing chlorogenic acid can be used in the preparation of a drug for treating the early Alzheimer's disease. In the pharmaceutical composition chlorogenic acid is used as a main active ingredient, and 3-coumaroylquinic acid is used as an auxiliary ingredient. The latter can effectively improve the therapeutic effect of chlorogenic acid for treating the early Alzheimer's disease.

Abstract: Provided herein are cannabinoid-ratio defined formulations suitable for use as an active pharmaceutical ingredient. Also provided are methods of making the cannabinoid-ratio defined formulations; pharmaceutical compositions comprising the cannabinoid-ratio defined formulations, and methods of using the pharmaceutical compositions for the treatment of Parkinsonian movement disorders, including Parkinson's disease, parkinsonism, and dopamine-related Parkinson's disease symptoms.

Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Abstract: The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders.